<DOC>
	<DOCNO>NCT00741325</DOCNO>
	<brief_summary>This long-term observational study patient treat least 1 dose study treatment ( plerixafor placebo ) AMD3100-3101 protocol ( NCT00103610 ) .</brief_summary>
	<brief_title>Long-Term Follow-up Study Non-Hodgkin 's Lymphoma Patients Who Received Study Treatment ( Plerixafor Placebo ) AMD3100-3101 Study ( NCT00103610 ) .</brief_title>
	<detailed_description>This long-term observational study patient receive least one dose study treatment ( plerixafor placebo ) multicenter , randomize , double blind , placebo-controlled investigational study evaluate granulocyte colony stimulate factor ( G-CSF ) plus AMD3100 versus G-CSF plus placebo mobilize transplant Non-Hodgkin 's Lymphoma ( NHL ) patient ( protocol AMD3100-3101 [ NCT00103610 ] ) . The objective study assess progression-free survival overall survival patient treat least 1 dose study treatment ( placebo plerixafor ) period 5 year follow first dose study treatment ( placebo plerixafor ) protocol AMD3100-3101 ( NCT00103610 ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>All patient receive dose study treatment ( plerixafor placebo ) protocol AMD31003101 ( NCT00103610 ) No Exclusion Criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>